Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlitelimab - Kymab/Sanofi

Next Previous
Drug Profile

Amlitelimab - Kymab/Sanofi

Alternative Names: KY-1005; SAR-445229

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymab
  • Developer Kymab; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Alopecia areata; Asthma; Autoimmune disorders; Coeliac disease; Hidradenitis suppurativa; Systemic scleroderma
  • No development reported Graft-versus-host disease

Most Recent Events

  • 15 Apr 2025 Efficacy and safety data from the phase II TIDE-asthma trial in Asthma released by Sanofi
  • 15 Apr 2025 Sanofi plans a phase III trial in Asthma (SC)
  • 20 Mar 2025 Sanofi completes the phase II TIDE-asthma trial in Asthma (Adjunctive treatment) in USA, Hungary, Argentina, Chile, Canada, Turkey, Poland, Mexico, South Korea, South Africa, United Kingdom, Japan, Italy, Brazil (SC, Injection) (NCT05421598) (EUCT2024-510641-33)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top